WuXi Biologics
WuXi Biologics is one of the leading global biologics CRDMO providers, offering end-to-end services across biologics discovery, development, clinical manufacturing, commercial manufacturing, and regulatory support. Its integrated research-development-manufacturing model gives it a differentiated position in the biologics outsourcing market.
- Highest 2026 tier: Tier I
- Biomanufacturing & CDMO Providers
- 1 ranking category
Overview
WuXi Biologics is one of the leading global biologics CRDMO providers, offering end-to-end services across biologics discovery, development, clinical manufacturing, commercial manufacturing, and regulatory support. Its integrated research-development-manufacturing model gives it a differentiated position in the biologics outsourcing market.
The company’s strength lies in project breadth and technical integration. WuXi Biologics supports monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates, recombinant proteins, and other biologic modalities. Its 2025 results reported 945 integrated projects, 209 new integrated projects signed, 28 completed process performance qualifications, and total backlog of $23.7 billion, showing the depth of its pipeline and sponsor base.
WuXi Biologics is included in 1 2026 ranking category. Its highest classification is Tier I. Ranking recognition is category-specific editorial evidence rather than a substitute for independent diligence.
Firm facts
| Public identity | WuXi Biologics |
| Founded | 2010 |
| Institution type | Biomanufacturing & CDMO Providers institution |
| Headquarters | Wuxi / Hong Kong, China |
| Primary focus | Biomanufacturing & CDMO Providers |
| Highest 2026 ranking tier | Tier I |
Principal activities
The company’s strength lies in project breadth and technical integration. WuXi Biologics supports monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates, recombinant proteins, and other biologic modalities. Its 2025 results reported 945 integrated projects, 209 new integrated projects signed, 28 completed process performance qualifications, and total backlog of $23.7 billion, showing the depth of its pipeline and sponsor base.
Core capability
Biomanufacturing & CDMO Providers
Client relevance
Category-specific capability, institutional credibility and the ability to support demanding professional, commercial or patient needs.
Execution and verification
Current service scope, leadership, geographic coverage, legal entities and regulated activities should be confirmed directly.
Sector and mandate coverage
Primary category
Biomanufacturing & CDMO Providers
Institutional context
Coverage reflects the institution’s role in the ranking categories listed below. Precise services, products, jurisdictions, clinical scope and client eligibility should be verified for each use case.
Market position
Geopolitical risk remains a monitoring factor given the company’s China origin and U.S.-China life sciences policy uncertainty. Nevertheless, WuXi Biologics’ technical capabilities, project scale, CRDMO model, and biologics specialization support its Tier I position.
WuXi Biologics is assessed through public institutional information and Ranking News editorial research. Its strongest 2026 result is Tier I.
Competitive context
The relevant peer set varies by category, geography, client segment and mandate. WuXi Biologics should be compared on current category-specific capability, senior involvement, evidence of comparable work, operating resilience and any applicable regulatory or clinical permissions.
Comparable institutions are shown for navigation and market context. Inclusion does not imply identical scale, ownership, geographic coverage, service model or regulatory status.
Leadership and governance
Leadership, ownership, governance and senior-team responsibilities may change. Current information should be verified through authoritative institutional sources.
Corporate and public information
The public-facing organization is identified here as WuXi Biologics. Contracting entities, regulated affiliates, clinical operations, offices and legal permissions may differ by service and jurisdiction.
Corporate and disclosure information
| Organization | WuXi Biologics |
| Headquarters | Wuxi / Hong Kong, China |
| Verification note | Confirm legal entity, licenses, offices and engagement terms directly before appointment or use. |
Rankings and recognition
Ranking inclusion and tier classification are editorial determinations. They should be read as category-specific assessments rather than universal league-table positions. The existence or maintenance of this Wiki profile does not influence ranking eligibility, tier or position.
Related Economy analysis
Selected reporting and market analysis from The Economy provides context for the institution’s operating environment:
- Healthcare Rankings and the New Economics of Expertise
- Healthcare Market Structure Is Opening a New Lane for Specialist Providers
- Healthcare Rankings and the New Geography of Distributed Care
Related institutions and subjects
Sources and data transparency
Official institutional information, where available, is used for current public identity and capabilities. Ranking pages document 2026 category and tier status. Economy articles provide market context rather than institution-specific endorsement.
- Healthcare Ranking — Top 30 Biomanufacturing & CDMO Providers 2026 — 2026 inclusion and tier classification.
- The Economy — Healthcare Rankings and the New Economics of Expertise — market context.
- The Economy — Healthcare Market Structure Is Opening a New Lane for Specialist Providers — market context.
- The Economy — Healthcare Rankings and the New Geography of Distributed Care — market context.
